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Abstract: RNA interference is not only an important tool for studying protein function; it also holds many promises for the treatment
of a variety of diseases in which the function of unwanted proteins needs to be suppressed. For small interfering RNA (siRNA) to be
used as a therapeutic agent, the biggest hurdle is to find the right delivery agent that is both nontoxic to the cells and efficient in delivery.
Synthetic and natural peptides from a variety of organisms have been investigated for this purpose. However, there is still no agent or
formulation that has been approved for siRNA delivery. Antimicrobial peptide LL-37 has been reported to deliver negatively charged
cargo molecules like DNA into the mammalian cells. Since it is nontoxic and nonimmunogenic, and it has the ability to penetrate
through mammalian cells in complex with negatively charged molecules, LL-37 peptide appears to make an ideal delivery agent for
siRNA therapy. In this report, LL-37/siRNA complexes have been characterized and LL-37-mediated transfection has been investigated
in vitro. The results show that the efficiency of delivery was dependent on the cell type, and for LL-37 to be used as a siRNA delivery
agent, conditions have to be optimized for each target tissue type.
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1. Introduction
RNA interference (RNAi) is a rapidly developing and
evolving field holding many promises for laboratory and
therapeutic applications. It was shown for the first time
in 1998, in Caenorhabditis elegans, (1) and since then,
this natural mechanism that takes part in the control of
the gene expression has been identified in a wide range
of organisms, from yeast to humans (2–4). RNAi is also
crucial as a defense mechanism against infections and
viruses, and it plays a key role during development (5).
This groundbreaking discovery was not only rapidly
adapted bench-side as a powerful and easy methodology
to study gene function in vitro, but it also emerged as a
revolutionary approach for the treatment of a variety
of diseases including cancer, viral infections, and
neurodegenerative diseases in clinical setting (4).
Most of the drugs on the market exert therapeutic
effects through interacting with proteins and cellular
receptors. However, RNAi-based approaches have an
enormous advantage, as they are aimed at the inhibition
of target protein production in the first place to provide
a long-lasting and relatively durable effect. In addition,
compared to conventional drugs that take years to develop,
designing and choosing the siRNAs against the target
gene(s) would require less time and will hopefully decrease
* Correspondence: sahru.yuksel@boun.edu.tr
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the cost of drug development. Theoretically, siRNAs can
be designed to interfere with the translation of almost any
mRNA, as long as the mRNA has a distinctive sequence
and the chosen siRNAs are thoroughly investigated to
not cause any nonspecific effects. This approach holds the
potential to create a therapy against diseases that are not
curable or are difficult to treat due to various reasons such
as unavailability of inhibitors.
With all these advantages, one of the major hurdles
that needs to be resolved for RNAi-based therapy is to
find delivery agents that are both nontoxic to the cells
and effectively transfer siRNA into the target cell upon
systemic administration. This is because siRNAs can be
rapidly degraded in circulation, or cleared from the system
and not effectively internalized due to their high molecular
weight and polyanionic nature when they are administered
alone (6,7). The most frequently studied delivery systems
for siRNA drugs for systemic administration are peptidebased systems, viral vectors, and polymer- or liposomebased systems. Mostly not being toxic at the doses that
can be used for administration, cationic peptides with cell
penetration properties offer an important advantage over
the other types of delivery systems, such as viral vectors
or polymer-based nanoparticles, that can cause toxicity or
immunogenicity and insertional mutagenesis problems
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(8). Each group has its own potentials and limitations,
which were extensively discussed in recent reviews (9–11).
Within the peptide group, there are synthetic peptides
such as poly-lysine and natural peptides from bacteria,
viruses, or others such as the HIV-1 trans-activator (Tat)
gene product (12), penetratin, and transportin, with the
ability to penetrate membranes and deliver cargo molecules
into the host cells. In general, these are cationic structures,
and the mechanism of membrane penetration is not fully
clear for all of them. For instance, with Tat-based delivery
systems, endosomal uptake is favored when the size of
the peptide nucleic acid complex is between 500 and 700
nm, whereas particles smaller than 300 nm do not utilize
this pathway (13). Unlike with viral systems, delivery of a
variety of cargo molecules with cell-penetrating peptides
include, but are not limited to, nucleic acids (6), proteins
(14), and quantum dots (15). There is a growing list of such
peptides that are extensively discussed in recent reviews
(11).
The fact that LL-37 has been shown to deliver
negatively charged cargo molecules such as genomic
DNA or plasmid DNA into the host cells prompted us
to investigate the possibility of whether this naturally
present molecule could be used as a siRNA therapy tool.
LL-37 is the only member of the cathelicidin family
of antimicrobial peptides in humans. The propeptide,
human cathelicidin-like antimicrobial peptide (hCAP18),
is secreted from activated neutrophils and the conserved
N terminal cathelin domain is cleaved off by protease 3,
secreted from activated neutrophils, leaving the functional
antimicrobial LL-37 (16). It is mainly expressed by bone
marrow cells, such as monocytes and neutrophils, and
epithelial cells of various organs in the body (17). The
concentration of LL-37 in human plasma was reported to
be 1.2–1.8 µg/mL for LL-37 and 1.18 µg/mL for hCAP18
(18). The ability of LL-37 to interact with DNA and LL37-mediated delivery of plasmid DNA to the nuclear
compartment was demonstrated for the first time in 2004
by Sandgreen et al. (19). In another groundbreaking study
by Lande et al., LL-37 was identified as a factor involved
in the internalization of genomic DNA by plasmacytoid
dendritic cells (pDCs) in psoriasis skin lesions (20). The
ability of LL-37 to make complexes with DNA was based
on the net 6 positive charge on the peptide and negative
charges on the backbone of DNA, and the complexed
nucleic acids were protected from degradation by serum
nucleases.
In this study, we report for the first time the
characterization of LL-37 and siRNA complexes, as well
as investigation of the LL-37-mediated delivery of these
complexes into several mammalian cell lines.

2. Materials and methods
LL-37, LL 8-37, and TAMRA-LL-37 were purchased from
Anaspec (Fremont, CA, USA) and resuspended in sterile
distilled deionized water. siRNA against green fluorescent
protein (GFP) was purchased from Dharmacon (Lafayette,
CO, USA) and resuspended to the desired molarity in
DEPC-treated phosphate buffered saline.
2.1. Gel shift assay
Peptide and siRNA were mixed in a final concentration of
10 mM HEPES (pH 7.4) at various peptide/siRNA charge
ratios and incubated for 30 min at room temperature.
Charge ratios were calculated as previously described
(21). The mixture was run on a 15% nondenaturing
polyacrylamide gel electrophoresis at 100 V for 2 h in 1X
TBE and visualized by ethidium bromide staining.
2.2. Heparin release assay
Peptide/siRNA complexes were prepared at a 5:1 charge
ratio as described above, then heparin (Wockhardts,
France) was added at various concentrations (0.5 units
to 0.02 units) and the mixture was incubated for 10 min
at room temperature. The mixtures were run on a 15%
nondenaturing PAGE at 100 V for 2 h in 1X TBE and
visualized by ethidium bromide staining.
2.3. Particle size analysis
Peptide/siRNA complexes at a 5:1 charge ratio were
visualized by scanning tunneling electron microscopy
(STEM). A drop of sample mixture (approximately 20 µL)
was loaded on carbon-coated copper 400-mesh grids. It
was then incubated at room temperature for the formation
of thin film and analyzed with an XL30 ESEM-FEG/EDAX
in STEM mode (Philips Global). Liquid state analysis for
the particle size was done with a Brookhaven Instruments
90 Plus Particle Size Analyzer at room temperature. An
average of 10 measurements were taken for each data
point.
2.4. Confocal microscopy
SKBR3 breast cancer cells were seeded on cover slips
overnight. The next day, the cells were treated overnight
in serum-free media with FITC-GFP siRNA (130 nM)
(Invitrogen, USA) and TAMRA-LL-37 (17.5 µg/mL)
complex. The cells were then washed extensively with PBS
and 1 M NaCl to remove uninternalized peptide–siRNA
complexes and then fixed in 4% paraformaldehyde. The
FITC signal was amplified with TSA plus fluorescence
systems (PerkinElmer, USA) according to instructions
provided by the manufacturer and visualized with a Leica
SP2 AOBS (Wetzlar, Germany). Nuclei were stained with
DAPI.
2.5. Lentiviral transduction
Lentivirus production was carried out in packaging cell
line HEK-293 FT for stable transduction of the HCC1143
cell line with lentiviruses expressing eGFP. The 4-plasmid
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system (pHCMV-G, pRSV-Rev, pMDLg/pRRE, and
fg12GFP) was a gift from MS Soengas and was used to
transfect HEK-293 FT cells by the calcium phosphate
method. Two days after the transfection, the supernatant
containing the viral particles was filtered through a 0.45
µM filter and incubated with HCC1143 cells for 8 h in the
presence of polybrene. Fresh medium was then added and
cells were passaged several times for the stabilization of
GFP expression before being used in the experiments.
2.6. Cell culture and transfection with LL-37 complexes
HEK-293 FT (human embryonic kidney cells), Huh7 (human hepatocellular carcinoma), MCF-7 (human
breast adenocarcinoma cell line), MDA-MB 231
(human breast carcinoma cell line), SKBR3 (human
breast adenocarcinoma cell line), HeLa (human cervical
adenocarcinoma), HT-29 (human colon adenocarcinoma
cell line), SKMEL (human skin melanoma cell line), and
HCC1143 (human breast adenocarcinoma cell line) were
propagated in media as suggested by the American Type
Culture Collection. Cells were seeded overnight in 96-well
plates with about 70% confluency. Complexes of pEGFPc3
and LL-37 peptide were prepared in different charge ratios
in a serum-free medium and incubated with the cells. After
24 h, serum-free media containing the complexes were
replaced with the regular growth medium. Fluorescence
was monitored with fluorescence microscopy for up to 1
week.
3. Results and discussion
3.1. Characterization of LL-37 siRNA complexes
Gel shift analysis indicated that efficient complex formation
between LL-37 and siRNA starts at a charge ratio of 3:1
and is mostly completed at a ratio of 5:1 (Figure 1a).
The ability of complexes was analyzed in the presence of
heparin, a highly anionic substance for competition with
siRNA. The complexes were able to dissociate from each
other at saturating levels of heparin, as shown in Figure 1b.
In order to determine the size and the stability of the
formed complexes, electron microscopy and a nanoparticle
size analyzer based on dynamic light scattering were used.
According to the electron microscopy analysis, the particle
size varied between 68 and 123 nm (mean: 90.8 ± 21.3)
(Figure 1c), and with the nanosizer an average effective
diameter of 186.4 ± 5 nm was obtained. Measurements of
the complexes in solution showed that complexes retained
approximately the same average effective diameter for
around 42 h, suggesting that the complexes were very
stable and do not degrade easily (Figures 1d and 1e). The
slight differences in the size of the complexes measured by
these 2 different instruments is most likely due to different
states of the material at the time of analysis (in solution
vs. dry).
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3.2. Internalization of LL-37/siRNA complexes
The ability of LL-37 peptide-mediated internalization
of siRNA was investigated by confocal microscopy.
According to the data obtained, FITC-labeled siRNA was
efficiently internalized and detected within the cytoplasm
and perinuclear regions of the SKBR3 cells when delivered
in complex with TAMRA-labeled LL-37 (Figure 2), but not
when incubated alone with the cells. Most of the siRNA
was detected as still complexed with LL-37, possibly
in the endosomal compartment as conferred from the
distinct punctual appearance. Another factor pointing
toward the endosomal uptake mechanism for LL-37mediated delivery was supported by the observation that
the use of chloroquine, a weak base that inhibits lysosomal
acidification, increased the efficiency of transfection
(unpublished observation).
According to the study by Sandgreen et al. (19), LL-37
facilitates the delivery of plasmid DNA into the nucleus
of mammalian cell lines. The fact that siRNA and LL-37
complexes were also detected in nuclear compartments of
some of the cells in our study suggests that, independent
of the nature of the cargo particle in complex with LL37, some of the internalized material may end up in the
nucleus.
3.3. LL-37-mediated silencing in vitro
Since the internalization with LL-37 was reported to be
dependent on the lipid raft and proteoglycan composition
of the target cell (19), we wanted to determine what kind
of cells were more readily taking up LL-37 complexes.
Nine cell lines, including HEK-293 FT, Huh-7, MCF7, MDA-MB 231, HeLa, HT-29, SKMEL, SKBR3, and
HCC1143, were used for this purpose. When LL-37/
pEGFP complexes were transfected, not all of the cell types
expressed the GFP with the same efficiency as expected.
The most efficient transfection with pEGFP in complex
with LL-37 was achieved with the HCC1143 breast cancer
cell line.
The differences in the efficiency of internalization via
these different cell types could be due to differences in the
plasma membrane composition and lipid raft formation
that might depend on parameters such as the amount of
cholesterol, glycosphingolipids, types of phospholipids, and
protein composition. The composition of the extracellular
matrix of these cell types could also possibly influence the
degree of uptake and the intracellular localization of these
complexes.
Next, to determine the efficiency of gene silencing
with LL-37, a cell line of HCC1143 stably expressing
eGFP (HCC1143-GFP) was generated through lentiviral
transduction. When LL-37/GFP siRNA complexes were
incubated with HCC1143-GFP cells, partial silencing of
GFP fluorescence was observed (Figure 3). The fragment
of LL-37 extending from 8–37 amino acids was also tested
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Figure 1. Characterization of LL-37/siRNA complexes: a) formation of complexes at increasing peptide charge ratio analyzed by
gel shift assay; b) dissociation of the complexes prepared at 5:1 ratio by the addition of decreasing amounts of heparin; c) electron
microscopy analysis of complexes prepared at 5:1 charge immediately and d) after 42 h of incubation at room temperature; e) liquid
state analysis of complexes as by nanosizer at room temperature.

as an alternative to the full-length mature peptide. This
fragment of LL-37, to a similar extent, was also able to
induce GFP knockdown in HCC1143 GFP cells (Figure 3).
It may be the increased amount of cytoplasmic siRNA, as
opposed to endosomal siRNA, resulting in some silencing
observed in HCC1143 cells. As opposed to the earlier
literature reporting endosomal localization in human

pDCs treated with LL-37 genomic DNA complexes (20),
in a very recent report, DNA was mostly (>70%) localized
to cytoplasm after 24 h of incubation with LL-37-genomic
DNA complexes in human monocytes (22). Among the
primary human keratinocytes, fibroblasts, mature dendritic
cells, and pDCs tested in this study, very high cytoplasmic
localization of DNA was only seen in monocytes, and this
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Figure 2. Localization of LL-37/siRNA complexes. Confocal images of SKBR3 cells treated with
complexes prepared at 4:1 charge ratio of TAMRA-LL-37 (shown in red) and FITC GFP siRNA
(shown in green) after overnight incubation in serum free media: a) peptide, b) nucleus, c)
siRNA and d) overlay.

was independent of the sequence of the DNA. Based on
this study, it is possible to speculate that LL-37-mediated
delivery of siRNA and knockdown would be similarly
very high in primary human monocytes. It still remains
to be investigated how the LL-37-mediated delivery of the
same cargo molecule results in such different subcellular
localization in these 2 cell types. Understanding the
mechanism might help us to find out which cells are more
suitable for LL-37-mediated siRNA delivery and gene
knockdown.
In conclusion, this work suggests that LL-37 might be
useful for the delivery of siRNA to some cell lines. However,
it is important to keep in mind that, based on the target
tissues, sometimes slight modifications or manipulations
might also be useful. For instance, it was reported that
the incorporation of a polyhistidine tag to Tat peptide
increased the efficiency of delivery by 7000-fold (23). The
fact that some LL-37 complexes were shown to localize
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to the nuclear compartment in this and earlier reports also
suggests that LL-37 has the potential to be used for gene
silencing when used for delivery in complex with small
hairpin RNA (shRNA). The degree of nuclear localization
might differ in different cell types and individual testing and
optimization might be required. More excitingly, the recent
literature on primary cells supports the idea that LL-37mediated delivery might even be more promising in human
monocytes, which remains to be tested.
It is highly likely that LL-37 might have some
physiological role in the manipulation of the gene expression,
such as making complexes with the microRNAs that can be
found in the circulation and delivering them to another cell,
since both the LL-37 peptides and microRNAs are shown
to exist in the circulation. If this is shown to be true, such a
mechanism would not only reveal a new way of intracellular
communication mechanism, but also might have diagnostic
and prognostic implications for some diseases.
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Figure 3. LL-37 mediated GFP knockdown in HCC1143-GFP cells. HCC1143-GFP cells were incubated with LL-37/GFP siRNA
complexes for 24 h in serum-free media. Pictures were taken 48 h after the addition of fresh media. Fluorescence and bright field
images of: a) untreated HCC1143-GFP cells, b) HCC1143-GFP treated with complexes prepared at 4:1 LL-37 to GFP siRNA charge
ratio, and c) LL8-37-GFP siRNA complexes prepared at 3:1 ratio.
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